Clinicians must carefully question our patients about the source of their prescription drugs to make sure they are obtaining these products from legitimate sources.
Greater cooperation needed between federal and state health inspectors to oversee compounding pharmacies, which fall into a regulatory gray zone between various state and federal laws.
Drug manufacturer Qualitest has issued a nationwide voluntary recall of one lot of hydrocodone bitartrate and acetaminophen 10mg/500mg tablets due to potentially over-sized tablets.
The FDA has approved bosutinib (Bosulif, Pfizer) for patients with chronic, accelerated or blast phase Philadelphia chromosome positive CML, who are resistant to or who cannot tolerate other therapies.
The FDA has approved tbo-filgrastim to treat neutropenia in patients with nonmyeloid malignancies, who receive myelosuppressive chemotherapy.
The first pediatric form of the cancer drug everolimus has been sanctioned to treat rare brain tumors in children aged 1 year and older.
Linzess sanctioned for constipation that does not respond to conventional treatment.
FDA warns that counterfeit drug may be ineffective and potentially harmful.